Articles tagged with Radiation Therapy
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A study documents elite-level strength training during active breast cancer treatment, showing rare retention of squat strength despite chemotherapy. LaShae Rolle, a competitive powerlifter and breast cancer survivor, completed the first-of-its-kind study, demonstrating the feasibility of high-intensity training when carefully managed.
Researchers have discovered a key role of centrosomes in signaling cells to proliferate despite DNA damage, enabling cancer resistance. The study suggests targeting Polo-like kinase 1 could prevent adaptation to therapy-induced DNA damage and drug resistance.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.
A new AI tool, iSeg, has been developed to accurately outline lung tumors on CT scans and identify areas that may be missed by doctors. The study found that iSeg consistently matched expert outlines across hospitals and scan types, and flagged additional areas that some doctors missed.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
Mayo Clinic has opened its first carbon ion therapy program in the Western Hemisphere, providing new hope for patients with treatment-resistant cancers. The Duan Family Building will also offer advanced proton therapy and other cancer treatments.
The CompassHER2 trial found that neoadjuvant THP led to a pathologic complete response (pCR) rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer. Lower ER expression levels resulted in higher pCR rates among ER-positive tumors.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers have identified conditions under which ultra-high dose rate carbon ion beams can spare normal cells while maintaining tumor control, opening new possibilities for safer radiotherapy. The study reveals a cell-sparing effect under normoxic conditions using higher linear energy transfer values.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
A 10-year study confirms a one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week regimen for early-stage breast cancer patients. This shorter schedule provides similar cancer control without additional long-term side effects.
A Phase III trial shows molecular profiling can safely reduce radiation for women with early-stage endometrial cancer, tailoring treatment to individual tumour characteristics. Nearly half of patients can be spared radiotherapy without compromising cancer control.
New studies showcase radiotherapy's potential as a curative treatment for rectal cancer, offering safer alternatives to surgery. Reduced-dose treatments and immunotherapy-combined regimens have improved tumour control and reduced side effects.
A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
A study found that most head-and-neck cancer survivors who underwent radiation don't know about survivorship care, despite grapple with side effects such as dry mouth, swallowing problems, and psychological distress. The survey also found that 40% of survivors still struggle with dry mouth and nearly a quarter reported trouble swallowing.
Researchers from the University of Cincinnati Cancer Center presented abstracts highlighting contrasting effects of a protein on head and neck, breast, and lung cancers. The study found increased levels of IL-9 in patients with head and neck cancer correlated with decreased survival, while elevated IL-9 was associated with smaller tumo...
Hyperbaric oxygen treatment has been shown to provide long-term relief for patients with late radiation-induced injuries, improving symptoms of urinary incontinence, bleeding, and severe pain. The treatment can lead to the healing of chronic injuries and allow patients to live a fully normal life.
A patient with adenoid cystic carcinoma was successfully treated with step-and-shoot proton arc therapy at Corewell Health William Beaumont University Hospital. The treatment showed minimal side effects, including only light skin discoloration, and the patient remains cancer-free.
Researchers at MD Anderson Cancer Center have discovered that adding copper-loaded agents to radiotherapy can overcome radioresistance in preclinical models of thoracic cancer. A novel blood-based biomarker, OSMR, has also been identified in patients with acute myeloid leukemia (AML), which shows prognostic potential and can help ident...
A new study found that mesenchymal stem cell-derived extracellular vesicles significantly enhance survival and facilitate substantial peripheral blood recovery in mice exposed to high-dose irradiation. The treatment promoted hematopoietic recovery, with increases in red blood cell, platelet, white blood cell, and hemoglobin levels.
A UCLA study validates the predictive power of PROSTOX, a genetic test that uses microRNAs to identify patients at higher risk of developing long-lasting urinary side effects from radiation therapy. The test helps doctors and patients choose safer treatment options, reducing the burden of long-term complications.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
A study published in Plastic and Reconstructive Surgery reports that breast-conserving therapy, including radiation therapy, leads to progressive breast volume loss over time. Women with larger breasts experience greater total breast shrinkage, highlighting the need to discuss long-term changes in breast volume with patients.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers aim to transform rectal cancer into a disease treatable with radiation therapy, avoiding long-term surgery side effects. Papaverine is investigated as a sensitizer that boosts oxygen content in tumor cells, allowing for maximal tumor destruction.
A natural citrus oil, when combined with a lipid formulation, may effectively relieve dry mouth in cancer patients. The new formula has demonstrated improved solubility and bioavailability compared to pure limonene.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers have uncovered a key mechanism involving Intermolecular Coulombic Decay (ICD) in aqueous environments initiated by heavy-ion irradiation, providing insights into the effectiveness of such irradiation. This process significantly increases the biological effectiveness of heavy-ion therapy.
A new study confirms that a shorter, higher-dose-per-day radiation course is as effective as conventional radiotherapy for treating early-stage prostate cancer without increasing side effects. The study found similar cancer control rates and fewer gastrointestinal issues with the new approach.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
Researchers found that the current standard monitoring time of one-and-a-half to two months following surgery is too short to accurately identify recurrence and inform treatment decisions. Monitoring PSA levels for at least three months can avoid overtreatment and mislabel patients as having recurred.
Researchers at Waseda University develop a new imaging technique that uses neutron activation to transform gold nanoparticles into radioisotopes, enabling long-term tracking of their movement in the body. This breakthrough could lead to more effective cancer treatments and precision monitoring of drug distribution.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A Phase 2 clinical trial found that a neoadjuvant chemo-immunotherapy regimen achieved a 53% deep response rate, exceeding historical data with chemotherapy alone. The treatment approach led to impressive survival outcomes and fewer toxic side effects in patients with advanced HPV-negative head and neck cancer.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
A consensus statement by the Chinese College of Interventionalists promotes CBCT use in liver malignancy therapies, addressing limitations and challenges. The integration of artificial intelligence and technological innovations are expected to refine CBCT's efficacy and safety.
Researchers investigated radiation-induced cardiomyopathy management strategies to mitigate cardiac damage. The review discusses pathophysiology, clinical implications, and treatment options, including antioxidant medications and herbal supplements.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers at Huntsman Cancer Institute found that short-course, higher dose vaginal brachytherapy for endometrial cancer was as effective as more frequent, lower dose sessions in similar outcomes and few acute toxicities. The study aims to improve cancer care for patients across the Mountain West region.
A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.
Researchers developed a novel microscopy technique to study metabolic changes in individual cancer cells at the single-cell level. They found that radiation treatment caused significant metabolic shifts in head and neck squamous cell carcinoma cells, particularly through the activation of HIF-1α.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
A novel approach transforms treatment for pancreatic cancer by repurposing WR-2721 to protect healthy tissue from radiation damage. Phase 1 and 2 clinical trials are underway to evaluate the safety and efficacy of the new therapy, which could add years of survival to patients.